scholarly journals Characterization of the Coagulant Activity of Cultured Human Fibroblasts

Blood ◽  
1971 ◽  
Vol 37 (1) ◽  
pp. 47-51 ◽  
Author(s):  
DAVID GREEN ◽  
CATHY RYAN ◽  
NANCY MALANDRUCCOLO ◽  
HENRY L. NADLER

Abstract Skin fibroblasts were cultured from normal individuals, from patients with hemophilia, and from known and suspected carriers of hemophilia. All cell lysates studied had similar coagulant activity unaffected by incubation with a specific antibody to factor VIII and, therefore, presumably not factor VIII. Further investigation indicated that the coagulant had many properties indistinguishable from those associated with "tissue factor," including heat lability, sedimentation characteristics, and dependency on factor VII for expression of coagulant activity. The presence of tissue factor in skin fibroblasts is consistent with the wide distribution of this coagulant, and the ability to maintain this material in tissue culture provides an opportunity for further investigation of the role of tissue factor in normal and pathologic states.

2000 ◽  
Vol 31 (3) ◽  
pp. 233-242 ◽  
Author(s):  
Enikö Bazsó-Dombi ◽  
Katalin Oravecz ◽  
Florence Jeney ◽  
Katalin Nagy ◽  
Imre Zs.-Nagy

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 17-17
Author(s):  
Dougald Monroe ◽  
Mirella Ezban ◽  
Maureane Hoffman

Background.Recently a novel bifunctional antibody (emicizumab) that binds both factor IXa (FIXa) and factor X (FX) has been used to treat hemophilia A. Emicizumab has proven remarkably effective as a prophylactic treatment for hemophilia A; however there are patients that still experience bleeding. An approach to safely and effectively treating this bleeding in hemophilia A patients with inhibitors is recombinant factor VIIa (rFVIIa). When given at therapeutic levels, rFVIIa can enhance tissue factor (TF) dependent activation of FX as well as activating FX independently of TF. At therapeutic levels rFVIIa can also activate FIX. The goal of this study was to assess the role of the FIXa activated by rFVIIa when emicizumab is added to hemophilia A plasma. Methods. Thrombin generation assays were done in plasma using 100 µM lipid and 420 µM Z-Gly-Gly-Arg-AMC with or without emicizumab at 55 µg/mL which is the clinical steady state level. The reactions were initiated with low (1 pM) tissue factor (TF). rFVIIa was added at concentrations of 25-100 nM with 25 nM corresponding to the plasma levels achieved by a single clinical dose of 90 µg/mL. To study to the role of factor IX in the absence of factor VIII, it was necessary to create a double deficient plasma (factors VIII and IX deficient). This was done by taking antigen negative hemophilia B plasma and adding a neutralizing antibody to factor VIII (Haematologic Technologies, Essex Junction, VT, USA). Now varying concentrations of factor IX could be reconstituted into the plasma to give hemophilia A plasma. Results. As expected, in the double deficient plasma with low TF there was essentially no thrombin generation. Also as expected from previous studies, addition of rFVIIa to double deficient plasma gave a dose dependent increase in thrombin generation through activation of FX. Interestingly addition of plasma levels of FIX to the rFVIIa did not increase thrombin generation. Starting from double deficient plasma, as expected emicizumab did not increase thrombin generation since no factor IX was present. Also, in double deficient plasma with rFVIIa, emicizumab did not increase thrombin generation. But in double deficient plasma with FIX and rFVIIa, emicizumab significantly increased thrombin generation. The levels of thrombin generation increased in a dose dependent fashion with higher concentrations of rFVIIa giving higher levels of thrombin generation. Conclusion. Since addition of FIX to the double deficient plasma with rFVIIa did not increase thrombin generation, it suggests that rFVIIa activation of FX is the only source of the FXa needed for thrombin generation. So in the absence of factor VIII (or emicizumab) FIX activation does not contribute to thrombin generation. However, in the presence of emicizumab, while rFVIIa can still activate FX, FIXa formed by rFVIIa can complex with emicizumab to provide an additional source of FX activation. Thus rFVIIa activation of FIX explains the synergistic effect in thrombin generation observed when combining rFVIIa with emicizumab. The generation of FIXa at a site of injury is consistent with the safety profile observed in clinical use. Disclosures Monroe: Novo Nordisk:Research Funding.Ezban:Novo Nordisk:Current Employment.Hoffman:Novo Nordisk:Research Funding.


Blood ◽  
1973 ◽  
Vol 41 (5) ◽  
pp. 671-678 ◽  
Author(s):  
Leo R. Zacharski ◽  
Leon W. Hoyer ◽  
O. Ross McIntyre

Abstract Immunologic methods were employed in an attempt to identify a potent procoagulant present in homogenates of human skin fibroblasts cultured in vitro. The activity of this procoagulant was restricted to the early stages of coagulation and was heretofore considered to be due to tissue factor (tissue thromboplastin, factor III) either alone or in combination with one or more of the first-stage coagulation factors (VIII, IX, XI, XII). The present studies demonstrated that procoagulant activity was not diminished by incubation with anti-VIII or anti-IX antibodies of human origin or with anti-VIII antibody of rabbit origin. Furthermore, cell culture homogenates failed to bind antifactor VIII antibody and did not contain an inhibitor of the reaction between factor VIII and its antibody. By contrast, procoagulant activity was obliterated by an antibody to tissue factor protein regardless of whether plasmas deficient in factor VIII, IX, XI, or XII were used in the assay system. The antitissue factor antibody failed to block the procoagulant effect after tissue factor had complexed factor VII. The procoagulant, therefore, consisted entirely of tissue factor.


Blood ◽  
2000 ◽  
Vol 95 (4) ◽  
pp. 1330-1335 ◽  
Author(s):  
Cornelis van 't Veer ◽  
Neal J. Golden ◽  
Kenneth G. Mann

Factor VII circulates as a single chain inactive zymogen (10 nmol/L) and a trace (∼10-100 pmol/L) circulates as the 2-chain form, factor VIIa. Factor VII and factor VIIa were studied in a coagulation model using plasma concentrations of purified coagulation factors with reactions initiated with relipidated tissue factor (TF). Factor VII (10 nmol/L) extended the lag phase of thrombin generation initiated by 100 pmol/L factor VIIa and low TF. With the coagulation inhibitors TFPI and AT-III present, factor VII both extended the lag phase of the reaction and depressed the rate of thrombin generation. The inhibition of factor Xa generation by factor VII is consistent with its competition with factor VIIa for TF. Thrombin generation with TF concentrations >100 pmol/L was not inhibited by factor VII. At low tissue factor concentrations (<25 pmol/L) thrombin generation becomes sensitive to the absence of factor VIII. In the absence of factor VIII, factor VII significantly inhibits TF-initiated thrombin generation by 100 pmol/L factor VIIa. In this hemophilia A model, approximately 2 nmol/L factor VIIa is needed to overcome the inhibition of physiologic (10 nmol/L) factor VII. At 10 nmol/L, factor VIIa provided a thrombin generation response in the hemophilia model (0% factor VIII, 10 nmol/L factor VII) equivalent to that observed with normal plasma, (100% factor VIII, 10 nmol/L factor VII, 100 pmol/L factor VIIa). These results suggest that the therapeutic efficacy of factor VIIa in the medical treatment of hemophiliacs with inhibitors is, in part, based on overcoming the factor VII inhibitory effect.


FEBS Letters ◽  
2004 ◽  
Vol 569 (1-3) ◽  
pp. 240-244 ◽  
Author(s):  
Amparo Gimeno ◽  
Rosa Zaragozá ◽  
Juan R Viña ◽  
Vicente J Miralles

2016 ◽  
Vol 4 (6) ◽  
pp. e12742 ◽  
Author(s):  
Junsuke Igarashi ◽  
Ryuji Okamoto ◽  
Tetsuo Yamashita ◽  
Takeshi Hashimoto ◽  
Sakiko Karita ◽  
...  

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 213-213
Author(s):  
Shabbir Ansari ◽  
Usha R. Pendurthi ◽  
L. Vijaya Mohan Rao

Abstract Tissue factor (TF) is the cellular cofactor for the serine protease coagulation factor VIIa (FVIIa). The TF-FVIIa complex formed on the cell surface initiates the coagulation cascade. It is believed that most of the TF molecules on the cell surface of a resting cell exist in an encrypted state with very little procoagulant activity. Encrypted TF must undergo decryption to become fully active. The exact mechanisms by which TF activity on the cell surface is regulated are unknown. Exposure of phosphatidylserine (PS) to the outer leaflet of the cell membrane is thought to play a critical role in TF decryption. Recent studies of molecular dynamics simulation of TF ectodomain in solution and on the surface of anionic phospholipids suggested a direct interaction of PS headgroups with specific residues in TF. At present, the role of the putative lipid interactive residues of TF in TF decryption is unknown. In the present study, we investigated the potential role of TF direct interaction with the cell surface lipids on basal TF activity as well as enhanced TF activity following the decryption using different TF mutants. Plasmids or adenoviral constructs encoding wild-type or mutant TF (mutations in the putative lipid binding region) were used to transduce TF expression in CHO-K1 or monocytic THP-1 cells, respectively. TF protein expression level at the cell surface and FVIIa binding to the cell surface TF were evaluated by radioligand binding studies using 125I-labeled TF mAb or FVIIa, respectively. TF-FVIIa coagulant activity on the cell surface was determined in FX activation assay. Data of these studies showed that all TF mutants were capable of interacting with FVIIa with no apparent defect. Out of the 9 selected TF mutants, five of them -TFS160A, TFS161A, TFS162A, TFK165A, and TFD180A-exhibited a similar or slightly higher TF coagulant activity to that of the wild-type TF. The specific activity of three mutants, TFK159A, TFS163A and TFK166A, was reduced substantially to a range of 40% - 70% of that of wild-type TF. Mutation of the glycine residue at the position 164 markedly abrogated the TF coagulant activity, resulting in ~90% loss of TF specific activity. Mutation of all nine lipid binding residues together (DLBR) did not further decrease the specific activity of TF anymore than that of mutation of G164 alone. Comparison of the present data with the published data on these mutants revealed that some of the TF residues that are critical for regulating TF activity on liposomes are not crucial for TF activity on the cell surface. To address whether the decreased FXa generation seen with the select TF variants is caused by changes in TF-membrane interaction or by the substrate interaction with TF/FVIIa complex, we performed Michaelis-Menten kinetics of FX activation for two of TF mutants (TFS163A and TFG164A). Results of this study suggested that there were no significant differences in Km values between wild-type TF and TF mutants (wild-type TF, 51 ± 14.6 nM; TFS163A, 68 ± 19.5 nM; TFG164A, 39 ± 18.4 nM, n=4). Interestingly, mutation of the selective residues in the lipid binding region failed to abrogate the PS-dependent TF decryption. The fold-increase in TF activity in cells expressing wild-type TF or TF variants was similar following cell activation with either HgCl2 or calcium ionomycin treatment. Annexin V markedly diminished the increased TF-FVIIa activation of FX in cells expressing wild-type TF as well as cells expressing the TF mutant (DLBR mutant). Overall, our data suggest that the regulation of TF activity at the cell surface milieu may be different from that of PC/PS vesicles and TF region other than earlier identified LBR may be responsible for enhancing TF activity following the PS exposure. Disclosures No relevant conflicts of interest to declare.


Sign in / Sign up

Export Citation Format

Share Document